enGene Therapeutics Inc. Comprehensive Income
enGene Therapeutics Inc. (ENGN) reported Comprehensive Income of -$32.71 million for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-08.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-09-08
- enGene Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-07-31 was -$32.71M.
- enGene Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-04-30 was -$30.53M.
- enGene Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-01-31 was -$29.71M.
- enGene Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-10-31 was -$37.56M.
- enGene Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$116.77M.
- enGene Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$54.74M.
- enGene Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$99.92M.
- enGene Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$23.30M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-07-31 | -$32.71M 10-Q · filed 2026-09-08 | -$63.24M derived: sum of 2 quarters · filed 2026-09-08 | -$92.94M 10-Q · filed 2026-09-08 | -$130.50M derived: sum of 4 quarters · filed 2026-09-08 |
| 2026-04-30 | -$30.53M 10-Q · filed 2026-06-15 | -$60.23M 10-Q · filed 2026-06-15 | -$97.79M derived: sum of 3 quarters · filed 2026-06-15 | -$127.02M derived: sum of 4 quarters · filed 2026-09-08 |
| 2026-01-31 | -$29.71M 10-Q · filed 2026-03-09 | -$67.27M derived: sum of 2 quarters · filed 2026-03-09 | -$96.50M derived: sum of 3 quarters · filed 2026-09-08 | -$122.00M derived: sum of 4 quarters · filed 2026-09-08 |
| 2025-10-31 | -$37.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-22 | -$66.79M derived: sum of 2 quarters · filed 2026-09-08 | -$92.30M derived: sum of 3 quarters · filed 2026-09-08 | -$116.77M 10-K · filed 2025-12-22 |
| 2025-07-31 | -$29.23M 10-Q · filed 2026-09-08 | -$54.74M derived: sum of 2 quarters · filed 2026-09-08 | -$79.21M 10-Q · filed 2026-09-08 | -$94.11M derived: sum of 4 quarters · filed 2026-09-08 |
| 2025-04-30 | -$25.51M 10-Q · filed 2026-06-15 | -$49.98M 10-Q · filed 2026-06-15 | -$64.88M derived: sum of 3 quarters · filed 2026-06-15 | -$79.03M derived: sum of 4 quarters · filed 2026-06-15 |
| 2025-01-31 | -$24.47M 10-Q · filed 2026-03-09 | -$39.37M derived: sum of 2 quarters · filed 2026-03-09 | -$53.52M derived: sum of 3 quarters · filed 2026-03-09 | -$68.50M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-10-31 | -$14.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-22 | -$29.04M derived: sum of 2 quarters · filed 2025-12-22 | -$44.03M derived: sum of 3 quarters · filed 2025-12-22 | -$54.74M 10-K · filed 2025-12-22 |
| 2024-07-31 | -$14.15M 10-Q · filed 2025-09-11 | -$29.13M derived: sum of 2 quarters · filed 2025-09-11 | -$39.84M 10-Q · filed 2025-09-11 | |
| 2024-04-30 | -$14.98M 10-Q · filed 2025-06-12 | -$25.70M 10-Q · filed 2025-06-12 | ||
| 2024-01-31 | -$10.71M 10-Q · filed 2025-03-10 | |||
| 2023-10-31 | -$99.92M 10-K · filed 2024-12-19 | |||
| 2022-10-31 | -$23.30M 10-K · filed 2024-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |